WO2015125367A1 - 抗ウイルス性組成物、抗ウイルス剤、光触媒およびウイルス不活性化方法 - Google Patents
抗ウイルス性組成物、抗ウイルス剤、光触媒およびウイルス不活性化方法 Download PDFInfo
- Publication number
- WO2015125367A1 WO2015125367A1 PCT/JP2014/080808 JP2014080808W WO2015125367A1 WO 2015125367 A1 WO2015125367 A1 WO 2015125367A1 JP 2014080808 W JP2014080808 W JP 2014080808W WO 2015125367 A1 WO2015125367 A1 WO 2015125367A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- copper
- antiviral composition
- antiviral
- composition according
- bivo
- Prior art date
Links
- 230000000840 anti-viral effect Effects 0.000 title claims abstract description 134
- 239000000203 mixture Substances 0.000 title claims abstract description 108
- 241000700605 Viruses Species 0.000 title claims abstract description 33
- 239000011941 photocatalyst Substances 0.000 title claims abstract description 28
- 239000003443 antiviral agent Substances 0.000 title claims abstract description 21
- 238000000034 method Methods 0.000 title claims abstract description 21
- 230000002779 inactivation Effects 0.000 title claims abstract description 12
- 150000002484 inorganic compounds Chemical class 0.000 claims abstract description 56
- 229910010272 inorganic material Inorganic materials 0.000 claims abstract description 46
- 150000001880 copper compounds Chemical class 0.000 claims abstract description 44
- 239000005749 Copper compound Substances 0.000 claims abstract description 39
- 230000000415 inactivating effect Effects 0.000 claims abstract description 13
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 65
- 239000010949 copper Substances 0.000 claims description 55
- 229910052802 copper Inorganic materials 0.000 claims description 48
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 claims description 38
- -1 copper halide Chemical class 0.000 claims description 29
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 27
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims description 19
- QPLDLSVMHZLSFG-UHFFFAOYSA-N Copper oxide Chemical compound [Cu]=O QPLDLSVMHZLSFG-UHFFFAOYSA-N 0.000 claims description 14
- 229910021536 Zeolite Inorganic materials 0.000 claims description 11
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 claims description 11
- 239000010457 zeolite Substances 0.000 claims description 11
- 229960004643 cupric oxide Drugs 0.000 claims description 6
- 150000004767 nitrides Chemical class 0.000 claims description 6
- 229910000365 copper sulfate Inorganic materials 0.000 claims description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 229940116318 copper carbonate Drugs 0.000 claims description 4
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 claims description 4
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical group [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 claims description 4
- GEZOTWYUIKXWOA-UHFFFAOYSA-L copper;carbonate Chemical compound [Cu+2].[O-]C([O-])=O GEZOTWYUIKXWOA-UHFFFAOYSA-L 0.000 claims description 4
- QYCVHILLJSYYBD-UHFFFAOYSA-L copper;oxalate Chemical compound [Cu+2].[O-]C(=O)C([O-])=O QYCVHILLJSYYBD-UHFFFAOYSA-L 0.000 claims description 4
- 229910021594 Copper(II) fluoride Inorganic materials 0.000 claims description 3
- QFVJLAYKIQBTGJ-UHFFFAOYSA-N [Cu+2].[Cu+2].[Cu+2].[Cu+2].[Cu+2].[Cu+2].[O-]B([O-])[O-].[O-]B([O-])[O-].[O-]B([O-])[O-].[O-]B([O-])[O-] Chemical compound [Cu+2].[Cu+2].[Cu+2].[Cu+2].[Cu+2].[Cu+2].[O-]B([O-])[O-].[O-]B([O-])[O-].[O-]B([O-])[O-].[O-]B([O-])[O-] QFVJLAYKIQBTGJ-UHFFFAOYSA-N 0.000 claims description 3
- 150000001450 anions Chemical class 0.000 claims description 3
- ODWXUNBKCRECNW-UHFFFAOYSA-M bromocopper(1+) Chemical compound Br[Cu+] ODWXUNBKCRECNW-UHFFFAOYSA-M 0.000 claims description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 3
- XTVVROIMIGLXTD-UHFFFAOYSA-N copper(II) nitrate Chemical compound [Cu+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O XTVVROIMIGLXTD-UHFFFAOYSA-N 0.000 claims description 3
- OMZSGWSJDCOLKM-UHFFFAOYSA-N copper(II) sulfide Chemical compound [S-2].[Cu+2] OMZSGWSJDCOLKM-UHFFFAOYSA-N 0.000 claims description 3
- GWFAVIIMQDUCRA-UHFFFAOYSA-L copper(ii) fluoride Chemical compound [F-].[F-].[Cu+2] GWFAVIIMQDUCRA-UHFFFAOYSA-L 0.000 claims description 3
- YRNNKGFMTBWUGL-UHFFFAOYSA-L copper(ii) perchlorate Chemical compound [Cu+2].[O-]Cl(=O)(=O)=O.[O-]Cl(=O)(=O)=O YRNNKGFMTBWUGL-UHFFFAOYSA-L 0.000 claims description 3
- LLVVIWYEOKVOFV-UHFFFAOYSA-L copper;diiodate Chemical compound [Cu+2].[O-]I(=O)=O.[O-]I(=O)=O LLVVIWYEOKVOFV-UHFFFAOYSA-L 0.000 claims description 3
- ZZBBCSFCMKWYQR-UHFFFAOYSA-N copper;dioxido(oxo)silane Chemical compound [Cu+2].[O-][Si]([O-])=O ZZBBCSFCMKWYQR-UHFFFAOYSA-N 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 150000002367 halogens Chemical class 0.000 claims description 3
- 150000007522 mineralic acids Chemical class 0.000 claims description 3
- VUCAVCCCXQVHAN-UHFFFAOYSA-L azane dichlorocopper Chemical compound N.Cl[Cu]Cl VUCAVCCCXQVHAN-UHFFFAOYSA-L 0.000 claims description 2
- ZQLBQWDYEGOYSW-UHFFFAOYSA-L copper;disulfamate Chemical compound [Cu+2].NS([O-])(=O)=O.NS([O-])(=O)=O ZQLBQWDYEGOYSW-UHFFFAOYSA-L 0.000 claims description 2
- PEVJCYPAFCUXEZ-UHFFFAOYSA-J dicopper;phosphonato phosphate Chemical compound [Cu+2].[Cu+2].[O-]P([O-])(=O)OP([O-])([O-])=O PEVJCYPAFCUXEZ-UHFFFAOYSA-J 0.000 claims description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims 1
- 235000011130 ammonium sulphate Nutrition 0.000 claims 1
- 229910002915 BiVO4 Inorganic materials 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 44
- 239000000725 suspension Substances 0.000 description 26
- 239000000243 solution Substances 0.000 description 19
- 239000002245 particle Substances 0.000 description 17
- 239000000463 material Substances 0.000 description 15
- 238000005259 measurement Methods 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 239000000843 powder Substances 0.000 description 12
- 238000011156 evaluation Methods 0.000 description 11
- 239000011230 binding agent Substances 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- PZNSFCLAULLKQX-UHFFFAOYSA-N Boron nitride Chemical compound N#B PZNSFCLAULLKQX-UHFFFAOYSA-N 0.000 description 8
- 239000011521 glass Substances 0.000 description 8
- 239000012153 distilled water Substances 0.000 description 7
- 230000001699 photocatalysis Effects 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 6
- 239000010419 fine particle Substances 0.000 description 6
- 239000002002 slurry Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 5
- 239000011164 primary particle Substances 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 229910052582 BN Inorganic materials 0.000 description 4
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 4
- 238000002441 X-ray diffraction Methods 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- QGLKJKCYBOYXKC-UHFFFAOYSA-N nonaoxidotritungsten Chemical compound O=[W]1(=O)O[W](=O)(=O)O[W](=O)(=O)O1 QGLKJKCYBOYXKC-UHFFFAOYSA-N 0.000 description 4
- 229910001930 tungsten oxide Inorganic materials 0.000 description 4
- 239000005751 Copper oxide Substances 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 3
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
- 229910052797 bismuth Inorganic materials 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 229910000431 copper oxide Inorganic materials 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 239000010408 film Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000005416 organic matter Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 229910052709 silver Inorganic materials 0.000 description 3
- 239000004332 silver Substances 0.000 description 3
- 241001515965 unidentified phage Species 0.000 description 3
- WUPHOULIZUERAE-UHFFFAOYSA-N 3-(oxolan-2-yl)propanoic acid Chemical compound OC(=O)CCC1CCCO1 WUPHOULIZUERAE-UHFFFAOYSA-N 0.000 description 2
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical compound C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 2
- 229910010413 TiO 2 Inorganic materials 0.000 description 2
- MCMNRKCIXSYSNV-UHFFFAOYSA-N Zirconium dioxide Chemical compound O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 description 2
- 239000000956 alloy Substances 0.000 description 2
- 229910045601 alloy Inorganic materials 0.000 description 2
- AWZACWPILWGEQL-UHFFFAOYSA-M azanium;copper(1+);sulfate Chemical compound [NH4+].[Cu+].[O-]S([O-])(=O)=O AWZACWPILWGEQL-UHFFFAOYSA-M 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229910052980 cadmium sulfide Inorganic materials 0.000 description 2
- 239000000919 ceramic Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- YEOCHZFPBYUXMC-UHFFFAOYSA-L copper benzoate Chemical compound [Cu+2].[O-]C(=O)C1=CC=CC=C1.[O-]C(=O)C1=CC=CC=C1 YEOCHZFPBYUXMC-UHFFFAOYSA-L 0.000 description 2
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 2
- WFIPUECTLSDQKU-UHFFFAOYSA-N copper;ethyl 3-oxobutanoate Chemical compound [Cu].CCOC(=O)CC(C)=O WFIPUECTLSDQKU-UHFFFAOYSA-N 0.000 description 2
- QNZRVYCYEMYQMD-UHFFFAOYSA-N copper;pentane-2,4-dione Chemical compound [Cu].CC(=O)CC(C)=O QNZRVYCYEMYQMD-UHFFFAOYSA-N 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 231100000507 endocrine disrupting Toxicity 0.000 description 2
- 230000003100 immobilizing effect Effects 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 150000001247 metal acetylides Chemical class 0.000 description 2
- 229910000480 nickel oxide Inorganic materials 0.000 description 2
- 238000006303 photolysis reaction Methods 0.000 description 2
- 230000015843 photosynthesis, light reaction Effects 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920000139 polyethylene terephthalate Polymers 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000004544 sputter deposition Methods 0.000 description 2
- 150000004763 sulfides Chemical class 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229920003002 synthetic resin Polymers 0.000 description 2
- 239000000057 synthetic resin Substances 0.000 description 2
- 239000010409 thin film Substances 0.000 description 2
- MTPVUVINMAGMJL-UHFFFAOYSA-N trimethyl(1,1,2,2,2-pentafluoroethyl)silane Chemical compound C[Si](C)(C)C(F)(F)C(F)(F)F MTPVUVINMAGMJL-UHFFFAOYSA-N 0.000 description 2
- 229910052720 vanadium Inorganic materials 0.000 description 2
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 1
- JXSRRBVHLUJJFC-UHFFFAOYSA-N 7-amino-2-methylsulfanyl-[1,2,4]triazolo[1,5-a]pyrimidine-6-carbonitrile Chemical compound N1=CC(C#N)=C(N)N2N=C(SC)N=C21 JXSRRBVHLUJJFC-UHFFFAOYSA-N 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229910018072 Al 2 O 3 Inorganic materials 0.000 description 1
- PIGFYZPCRLYGLF-UHFFFAOYSA-N Aluminum nitride Chemical compound [Al]#N PIGFYZPCRLYGLF-UHFFFAOYSA-N 0.000 description 1
- JLZQMIOCUGMMTK-UHFFFAOYSA-L C(CCC(=O)[O-])(=O)OC=O.[Cu+2].C(=O)OC(CCC(=O)[O-])=O Chemical compound C(CCC(=O)[O-])(=O)OC=O.[Cu+2].C(=O)OC(CCC(=O)[O-])=O JLZQMIOCUGMMTK-UHFFFAOYSA-L 0.000 description 1
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical compound [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- YXLXNENXOJSQEI-UHFFFAOYSA-L Oxine-copper Chemical compound [Cu+2].C1=CN=C2C([O-])=CC=CC2=C1.C1=CN=C2C([O-])=CC=CC2=C1 YXLXNENXOJSQEI-UHFFFAOYSA-L 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 229910052581 Si3N4 Inorganic materials 0.000 description 1
- 229910006404 SnO 2 Inorganic materials 0.000 description 1
- NRTOMJZYCJJWKI-UHFFFAOYSA-N Titanium nitride Chemical compound [Ti]#N NRTOMJZYCJJWKI-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 1
- 229920000122 acrylonitrile butadiene styrene Polymers 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- JRPBQTZRNDNNOP-UHFFFAOYSA-N barium titanate Chemical compound [Ba+2].[Ba+2].[O-][Ti]([O-])([O-])[O-] JRPBQTZRNDNNOP-UHFFFAOYSA-N 0.000 description 1
- 229910002113 barium titanate Inorganic materials 0.000 description 1
- KCLGATRJYMEERW-UHFFFAOYSA-N benzene-1,3-dicarboxylic acid;copper Chemical compound [Cu].OC(=O)C1=CC=CC(C(O)=O)=C1 KCLGATRJYMEERW-UHFFFAOYSA-N 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- INAHAJYZKVIDIZ-UHFFFAOYSA-N boron carbide Chemical compound B12B3B4C32B41 INAHAJYZKVIDIZ-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- MGIWDIMSTXWOCO-UHFFFAOYSA-N butanedioic acid;copper Chemical compound [Cu].OC(=O)CCC(O)=O MGIWDIMSTXWOCO-UHFFFAOYSA-N 0.000 description 1
- 229910000420 cerium oxide Inorganic materials 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229920006026 co-polymeric resin Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229940108925 copper gluconate Drugs 0.000 description 1
- 229940120693 copper naphthenate Drugs 0.000 description 1
- SBTSVTLGWRLWOD-UHFFFAOYSA-L copper(ii) triflate Chemical compound [Cu+2].[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F SBTSVTLGWRLWOD-UHFFFAOYSA-L 0.000 description 1
- FXGNPUJCPZJYKO-TYYBGVCCSA-L copper;(e)-but-2-enedioate Chemical compound [Cu+2].[O-]C(=O)\C=C\C([O-])=O FXGNPUJCPZJYKO-TYYBGVCCSA-L 0.000 description 1
- SVOAENZIOKPANY-CVBJKYQLSA-L copper;(z)-octadec-9-enoate Chemical compound [Cu+2].CCCCCCCC\C=C/CCCCCCCC([O-])=O.CCCCCCCC\C=C/CCCCCCCC([O-])=O SVOAENZIOKPANY-CVBJKYQLSA-L 0.000 description 1
- RSJOBNMOMQFPKQ-UHFFFAOYSA-L copper;2,3-dihydroxybutanedioate Chemical compound [Cu+2].[O-]C(=O)C(O)C(O)C([O-])=O RSJOBNMOMQFPKQ-UHFFFAOYSA-L 0.000 description 1
- AWSWAKKAIQTOLD-UHFFFAOYSA-L copper;2,3-dihydroxypropanoate Chemical compound [Cu+2].OCC(O)C([O-])=O.OCC(O)C([O-])=O AWSWAKKAIQTOLD-UHFFFAOYSA-L 0.000 description 1
- UCPROVVOIQFRKZ-UHFFFAOYSA-L copper;2-carboxy-5-hydroxyphenolate Chemical compound [Cu+2].OC1=CC=C(C([O-])=O)C(O)=C1.OC1=CC=C(C([O-])=O)C(O)=C1 UCPROVVOIQFRKZ-UHFFFAOYSA-L 0.000 description 1
- CMRVDFLZXRTMTH-UHFFFAOYSA-L copper;2-carboxyphenolate Chemical compound [Cu+2].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O CMRVDFLZXRTMTH-UHFFFAOYSA-L 0.000 description 1
- SEKCXMNFUDONGJ-UHFFFAOYSA-L copper;2-ethylhexanoate Chemical compound [Cu+2].CCCCC(CC)C([O-])=O.CCCCC(CC)C([O-])=O SEKCXMNFUDONGJ-UHFFFAOYSA-L 0.000 description 1
- HXXRDHUDBAILGK-UHFFFAOYSA-L copper;2-hydroxyacetate Chemical compound [Cu+2].OCC([O-])=O.OCC([O-])=O HXXRDHUDBAILGK-UHFFFAOYSA-L 0.000 description 1
- WMYBXRITVYIFCO-UHFFFAOYSA-N copper;2-hydroxybutanedioic acid Chemical compound [Cu].OC(=O)C(O)CC(O)=O WMYBXRITVYIFCO-UHFFFAOYSA-N 0.000 description 1
- DYROSKSLMAPFBZ-UHFFFAOYSA-L copper;2-hydroxypropanoate Chemical compound [Cu+2].CC(O)C([O-])=O.CC(O)C([O-])=O DYROSKSLMAPFBZ-UHFFFAOYSA-L 0.000 description 1
- SEVNKWFHTNVOLD-UHFFFAOYSA-L copper;3-(4-ethylcyclohexyl)propanoate;3-(3-ethylcyclopentyl)propanoate Chemical compound [Cu+2].CCC1CCC(CCC([O-])=O)C1.CCC1CCC(CCC([O-])=O)CC1 SEVNKWFHTNVOLD-UHFFFAOYSA-L 0.000 description 1
- HCRZXNOSPPHATK-UHFFFAOYSA-L copper;3-oxobutanoate Chemical compound [Cu+2].CC(=O)CC([O-])=O.CC(=O)CC([O-])=O HCRZXNOSPPHATK-UHFFFAOYSA-L 0.000 description 1
- PUHAKHQMSBQAKT-UHFFFAOYSA-L copper;butanoate Chemical compound [Cu+2].CCCC([O-])=O.CCCC([O-])=O PUHAKHQMSBQAKT-UHFFFAOYSA-L 0.000 description 1
- ZZBHLLYRFXFBLC-UHFFFAOYSA-N copper;decanedioic acid Chemical compound [Cu].OC(=O)CCCCCCCCC(O)=O ZZBHLLYRFXFBLC-UHFFFAOYSA-N 0.000 description 1
- OBITVTZBIATBCL-UHFFFAOYSA-L copper;decanoate Chemical compound [Cu+2].CCCCCCCCCC([O-])=O.CCCCCCCCCC([O-])=O OBITVTZBIATBCL-UHFFFAOYSA-L 0.000 description 1
- HFDWIMBEIXDNQS-UHFFFAOYSA-L copper;diformate Chemical compound [Cu+2].[O-]C=O.[O-]C=O HFDWIMBEIXDNQS-UHFFFAOYSA-L 0.000 description 1
- CRCKGIUJMFFISH-UHFFFAOYSA-N copper;ethanolate Chemical compound [Cu+2].CC[O-].CC[O-] CRCKGIUJMFFISH-UHFFFAOYSA-N 0.000 description 1
- NQDSPXCXIOLFGI-UHFFFAOYSA-L copper;heptanoate Chemical compound [Cu+2].CCCCCCC([O-])=O.CCCCCCC([O-])=O NQDSPXCXIOLFGI-UHFFFAOYSA-L 0.000 description 1
- GYPBUYJSHBFNEJ-UHFFFAOYSA-L copper;hexadecanoate Chemical compound [Cu+2].CCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCC([O-])=O GYPBUYJSHBFNEJ-UHFFFAOYSA-L 0.000 description 1
- ZCXLQZOQWCXFNN-UHFFFAOYSA-N copper;hexanedioic acid Chemical compound [Cu].OC(=O)CCCCC(O)=O ZCXLQZOQWCXFNN-UHFFFAOYSA-N 0.000 description 1
- AYNQPTYHFBBKFC-UHFFFAOYSA-N copper;methanolate Chemical compound [Cu+2].[O-]C.[O-]C AYNQPTYHFBBKFC-UHFFFAOYSA-N 0.000 description 1
- ZOUQIAGHKFLHIA-UHFFFAOYSA-L copper;n,n-dimethylcarbamodithioate Chemical compound [Cu+2].CN(C)C([S-])=S.CN(C)C([S-])=S ZOUQIAGHKFLHIA-UHFFFAOYSA-L 0.000 description 1
- HZULDDWVCRWYCB-UHFFFAOYSA-L copper;nonanoate Chemical compound [Cu+2].CCCCCCCCC([O-])=O.CCCCCCCCC([O-])=O HZULDDWVCRWYCB-UHFFFAOYSA-L 0.000 description 1
- VNZQQAVATKSIBR-UHFFFAOYSA-L copper;octanoate Chemical compound [Cu+2].CCCCCCCC([O-])=O.CCCCCCCC([O-])=O VNZQQAVATKSIBR-UHFFFAOYSA-L 0.000 description 1
- LMCVMQNMDSVUFJ-UHFFFAOYSA-N copper;pentanedioic acid Chemical compound [Cu].OC(=O)CCCC(O)=O LMCVMQNMDSVUFJ-UHFFFAOYSA-N 0.000 description 1
- NBPFTDFXKORRKN-UHFFFAOYSA-L copper;pentanoate Chemical compound [Cu+2].CCCCC([O-])=O.CCCCC([O-])=O NBPFTDFXKORRKN-UHFFFAOYSA-L 0.000 description 1
- GSCLWPQCXDSGBU-UHFFFAOYSA-L copper;phthalate Chemical compound [Cu+2].[O-]C(=O)C1=CC=CC=C1C([O-])=O GSCLWPQCXDSGBU-UHFFFAOYSA-L 0.000 description 1
- VNGORJHUDAPOQZ-UHFFFAOYSA-N copper;propan-2-olate Chemical compound [Cu+2].CC(C)[O-].CC(C)[O-] VNGORJHUDAPOQZ-UHFFFAOYSA-N 0.000 description 1
- PJBGIAVUDLSOKX-UHFFFAOYSA-N copper;propanedioic acid Chemical compound [Cu].OC(=O)CC(O)=O PJBGIAVUDLSOKX-UHFFFAOYSA-N 0.000 description 1
- LZJJVTQGPPWQFS-UHFFFAOYSA-L copper;propanoate Chemical compound [Cu+2].CCC([O-])=O.CCC([O-])=O LZJJVTQGPPWQFS-UHFFFAOYSA-L 0.000 description 1
- ZISLUDLMVNEAHK-UHFFFAOYSA-L copper;terephthalate Chemical compound [Cu+2].[O-]C(=O)C1=CC=C(C([O-])=O)C=C1 ZISLUDLMVNEAHK-UHFFFAOYSA-L 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- FWBOFUGDKHMVPI-UHFFFAOYSA-K dicopper;2-oxidopropane-1,2,3-tricarboxylate Chemical compound [Cu+2].[Cu+2].[O-]C(=O)CC([O-])(C([O-])=O)CC([O-])=O FWBOFUGDKHMVPI-UHFFFAOYSA-K 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003822 epoxy resin Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-M hexanoate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- DGAHKUBUPHJKDE-UHFFFAOYSA-N indium lead Chemical compound [In].[Pb] DGAHKUBUPHJKDE-UHFFFAOYSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- LIKBJVNGSGBSGK-UHFFFAOYSA-N iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Fe+3].[Fe+3] LIKBJVNGSGBSGK-UHFFFAOYSA-N 0.000 description 1
- 238000010409 ironing Methods 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- KEMQGTRYUADPNZ-UHFFFAOYSA-M margarate Chemical compound CCCCCCCCCCCCCCCCC([O-])=O KEMQGTRYUADPNZ-UHFFFAOYSA-M 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- CWQXQMHSOZUFJS-UHFFFAOYSA-N molybdenum disulfide Chemical compound S=[Mo]=S CWQXQMHSOZUFJS-UHFFFAOYSA-N 0.000 description 1
- 239000000025 natural resin Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- BMMGVYCKOGBVEV-UHFFFAOYSA-N oxo(oxoceriooxy)cerium Chemical compound [Ce]=O.O=[Ce]=O BMMGVYCKOGBVEV-UHFFFAOYSA-N 0.000 description 1
- GNRSAWUEBMWBQH-UHFFFAOYSA-N oxonickel Chemical compound [Ni]=O GNRSAWUEBMWBQH-UHFFFAOYSA-N 0.000 description 1
- BPUBBGLMJRNUCC-UHFFFAOYSA-N oxygen(2-);tantalum(5+) Chemical compound [O-2].[O-2].[O-2].[O-2].[O-2].[Ta+5].[Ta+5] BPUBBGLMJRNUCC-UHFFFAOYSA-N 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000005011 phenolic resin Substances 0.000 description 1
- VVOPUZNLRVJDJQ-UHFFFAOYSA-N phthalocyanine copper Chemical compound [Cu].C12=CC=CC=C2C(N=C2NC(C3=CC=CC=C32)=N2)=NC1=NC([C]1C=CC=CC1=1)=NC=1N=C1[C]3C=CC=CC3=C2N1 VVOPUZNLRVJDJQ-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 229920001225 polyester resin Polymers 0.000 description 1
- 239000004645 polyester resin Substances 0.000 description 1
- 229920005596 polymer binder Polymers 0.000 description 1
- 239000002491 polymer binding agent Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920005749 polyurethane resin Polymers 0.000 description 1
- UKDIAJWKFXFVFG-UHFFFAOYSA-N potassium;oxido(dioxo)niobium Chemical compound [K+].[O-][Nb](=O)=O UKDIAJWKFXFVFG-UHFFFAOYSA-N 0.000 description 1
- ZVJHJDDKYZXRJI-UHFFFAOYSA-N pyrroline Natural products C1CC=NC1 ZVJHJDDKYZXRJI-UHFFFAOYSA-N 0.000 description 1
- WOCIAKWEIIZHES-UHFFFAOYSA-N ruthenium(iv) oxide Chemical compound O=[Ru]=O WOCIAKWEIIZHES-UHFFFAOYSA-N 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- HBMJWWWQQXIZIP-UHFFFAOYSA-N silicon carbide Chemical compound [Si+]#[C-] HBMJWWWQQXIZIP-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- HQVNEWCFYHHQES-UHFFFAOYSA-N silicon nitride Chemical compound N12[Si]34N5[Si]62N3[Si]51N64 HQVNEWCFYHHQES-UHFFFAOYSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- GROMGGTZECPEKN-UHFFFAOYSA-N sodium metatitanate Chemical compound [Na+].[Na+].[O-][Ti](=O)O[Ti](=O)O[Ti]([O-])=O GROMGGTZECPEKN-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- VEALVRVVWBQVSL-UHFFFAOYSA-N strontium titanate Chemical compound [Sr+2].[O-][Ti]([O-])=O VEALVRVVWBQVSL-UHFFFAOYSA-N 0.000 description 1
- XOLBLPGZBRYERU-UHFFFAOYSA-N tin dioxide Chemical compound O=[Sn]=O XOLBLPGZBRYERU-UHFFFAOYSA-N 0.000 description 1
- 229910001887 tin oxide Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- UONOETXJSWQNOL-UHFFFAOYSA-N tungsten carbide Chemical compound [W+]#[C-] UONOETXJSWQNOL-UHFFFAOYSA-N 0.000 description 1
- ZNOKGRXACCSDPY-UHFFFAOYSA-N tungsten trioxide Chemical compound O=[W](=O)=O ZNOKGRXACCSDPY-UHFFFAOYSA-N 0.000 description 1
- LSGOVYNHVSXFFJ-UHFFFAOYSA-N vanadate(3-) Chemical compound [O-][V]([O-])([O-])=O LSGOVYNHVSXFFJ-UHFFFAOYSA-N 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N59/00—Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
- A01N59/16—Heavy metals; Compounds thereof
- A01N59/20—Copper
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
- A01N25/08—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests containing solids as carriers or diluents
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N59/00—Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
- A01N59/16—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
- A61L2/23—Solid substances, e.g. granules, powders, blocks, tablets
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J21/00—Catalysts comprising the elements, oxides, or hydroxides of magnesium, boron, aluminium, carbon, silicon, titanium, zirconium, or hafnium
- B01J21/06—Silicon, titanium, zirconium or hafnium; Oxides or hydroxides thereof
- B01J21/063—Titanium; Oxides or hydroxides thereof
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
- B01J23/70—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of the iron group metals or copper
- B01J23/76—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of the iron group metals or copper combined with metals, oxides or hydroxides provided for in groups B01J23/02 - B01J23/36
- B01J23/84—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of the iron group metals or copper combined with metals, oxides or hydroxides provided for in groups B01J23/02 - B01J23/36 with arsenic, antimony, bismuth, vanadium, niobium, tantalum, polonium, chromium, molybdenum, tungsten, manganese, technetium or rhenium
- B01J23/843—Arsenic, antimony or bismuth
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
- B01J23/70—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of the iron group metals or copper
- B01J23/76—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of the iron group metals or copper combined with metals, oxides or hydroxides provided for in groups B01J23/02 - B01J23/36
- B01J23/84—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of the iron group metals or copper combined with metals, oxides or hydroxides provided for in groups B01J23/02 - B01J23/36 with arsenic, antimony, bismuth, vanadium, niobium, tantalum, polonium, chromium, molybdenum, tungsten, manganese, technetium or rhenium
- B01J23/847—Vanadium, niobium or tantalum or polonium
- B01J23/8472—Vanadium
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J27/00—Catalysts comprising the elements or compounds of halogens, sulfur, selenium, tellurium, phosphorus or nitrogen; Catalysts comprising carbon compounds
- B01J27/24—Nitrogen compounds
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J29/00—Catalysts comprising molecular sieves
- B01J29/04—Catalysts comprising molecular sieves having base-exchange properties, e.g. crystalline zeolites
- B01J29/06—Crystalline aluminosilicate zeolites; Isomorphous compounds thereof
- B01J29/076—Crystalline aluminosilicate zeolites; Isomorphous compounds thereof containing arsenic, antimony, bismuth, vanadium, niobium, tantalum, polonium, chromium, molybdenum, tungsten, manganese, technetium or rhenium
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J35/00—Catalysts, in general, characterised by their form or physical properties
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J35/00—Catalysts, in general, characterised by their form or physical properties
- B01J35/30—Catalysts, in general, characterised by their form or physical properties characterised by their physical properties
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J35/00—Catalysts, in general, characterised by their form or physical properties
- B01J35/30—Catalysts, in general, characterised by their form or physical properties characterised by their physical properties
- B01J35/31—Density
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J35/00—Catalysts, in general, characterised by their form or physical properties
- B01J35/30—Catalysts, in general, characterised by their form or physical properties characterised by their physical properties
- B01J35/39—Photocatalytic properties
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J35/00—Catalysts, in general, characterised by their form or physical properties
- B01J35/60—Catalysts, in general, characterised by their form or physical properties characterised by their surface properties or porosity
Definitions
- the present invention relates to an antiviral composition for inactivating viruses, an antiviral agent and a photocatalyst containing the antiviral composition, and a method for inactivating viruses.
- Patent Document 2 describes that platinum-supported tungsten oxide particles exhibit antiviral activity under visible light irradiation.
- BiVO 4 Bismuth vanadate
- the band gap is about 2.3 eV, which is smaller than the band gap of titanium oxide, which is 3.0 to 3.2 eV. That is, light (visible light) on a longer wavelength side can be effectively used for the photocatalyst as compared with titanium oxide, which is well known as a photocatalytic material.
- BiVO 4 also has a report example as an organic matter decomposition photocatalyst.
- Patent Document 3 describes that BiVO 4 powder supporting silver fine particles or copper oxide fine particles exhibits high activity as a photocatalyst for photolysis of endocrine disrupting substances.
- Patent Document 1 a sample of CuO / TiO 2 is antiviral under ultraviolet irradiation (Examples 1 to 4, Comparative Examples 3 to 4), under visible light irradiation (Comparative Example 2), and in the dark (Comparative Example 1).
- the phage / virus inactivating agent described in Patent Document 1 has no antiviral activity even in the dark and under visible light irradiation, and therefore is expected to have no antiviral activity even under a white LED fluorescent lamp. Is done. For this reason, the application to the interior material of the phage virus inactivating agent described in Patent Document 1 is extremely limited. Although the platinum-supported tungsten oxide particles described in Patent Document 2 exhibit antiviral properties under visible light irradiation, platinum is extremely rare and expensive, and thus it is difficult to industrially use the platinum-supported tungsten oxide particles. It is.
- Patent Document 3 describes an excellent effect as a photocatalyst for endocrine disrupting substance photolysis of BiVO 4 powder supporting silver fine particles or copper oxide fine particles.
- Patent Document 3 does not describe antiviral activity.
- the photocatalyst material which is excellent in organic substance decomposition activity does not necessarily have excellent antiviral activity (for example, refer nonpatent literature 3). That is, since the expression mechanism of both effects is fundamentally different, there is no relationship between the excellent organic matter degrading activity and the excellent antiviral activity. For this reason, those skilled in the art have not even considered using BiVO 4 powder carrying silver fine particles or copper oxide fine particles as an antiviral agent.
- BiVO 4 is expensive, has a bright yellow color, and is difficult to industrially use even if the synthesis conditions are optimized.
- the present invention has been made to solve the above-described problems, and exhibits an antiviral composition, an antiviral agent, a photocatalyst, and a virus that exhibit excellent antiviral properties in a short time even in a bright place and a dark place.
- An object is to provide an inactivation method.
- the present inventors have found the BiVO 4, and an inorganic compound carrying BiVO 4, the composition containing a divalent copper compound, that exhibits excellent antiviral activity in the visible light irradiation and under the dark
- the present invention has been completed. That is, the present invention provides the following inventions [1] to [16].
- An antiviral composition containing an inorganic compound carrying BiVO 4 and a divalent copper compound [2] The antiviral composition according to the above [1], wherein the mass of BiVO 4 is 1 to 20 parts by mass with respect to 100 parts by mass of the inorganic compound. [3] The antiviral composition according to the above [1] or [2], wherein the inorganic compound is an oxide or a nitride. [4] The antiviral composition according to [3] above, wherein the inorganic compound is one or more selected from the group consisting of titanium oxide, zeolite, and iron oxide.
- the mass of copper element in the divalent copper compound is 0.01 to 20 parts by mass relative to 100 parts by mass of the total of the inorganic compound and BiVO 4.
- the divalent copper compound is (a) the following general formula (1): Cu 2 (OH) 3 X (1) (In the formula, X represents an anion) (B) Divalent copper halide, (c) Divalent copper inorganic acid salt, (d) Divalent copper organic acid salt, (e) Cupric oxide Any one of the above [1] to [5], which is one or more selected from the group consisting of: (f) copper sulfide, (g) copper (II) azide, and (h) copper silicate An antiviral composition as described in 1.
- X of general formula (1) is 1 type, or 2 or more types selected from the group which consists of halogen, the conjugate base of carboxylic acid, the conjugate base of inorganic acid, and OH.
- Antiviral composition [8] The antiviral composition according to [6] above, wherein X is one selected from the group consisting of Cl, CH 3 COO, NO 3 and (SO 4 ) 1/2 .
- the (b) divalent copper halide is one or more selected from the group consisting of copper chloride, copper fluoride and copper bromide. Composition.
- Divalent copper inorganic acid salt is copper sulfate, copper nitrate, copper iodate, copper perchlorate, copper oxalate, copper tetraborate, ammonium sulfate copper, amide copper sulfate, ammonium copper chloride,
- the antiviral composition according to [6] above which is one or more selected from the group consisting of copper pyrophosphate and copper carbonate.
- the antiviral composition according to [6] above, wherein the organic salt of (d) divalent copper is a divalent copper carboxylate.
- the virus is inactivated using the antiviral composition according to any one of [1] to [13] above, the antiviral agent according to [14] above, or the photocatalyst according to [15] above. , Virus inactivation method.
- an antiviral composition an antiviral agent, a photocatalyst, and a virus inactivation method that exhibit excellent antiviral properties in a short time in a light place and a dark place.
- FIG. 1 is a photograph of a backscattered electron image of the sample of Example 1.
- FIG. 2 is a photograph of the backscattered electron image of the sample of Example 5.
- the present inventors have used an antiviral composition containing an inorganic compound carrying BiVO 4 and a divalent copper compound, and are excellent in bright and dark places without ultraviolet light.
- the inventors have found that an antiviral composition, an antiviral agent, and a photocatalyst that express antiviral properties can be obtained, and the present invention has been conceived.
- the present invention will be described in detail, but the present invention is not limited to the following embodiments.
- “light place” means a place where visible light having a wavelength of 400 nm or more exists but ultraviolet light is not substantially present
- dark place means ultraviolet light. Including the place where there is no light.
- the antiviral composition of the present invention is a composition containing an inorganic compound carrying BiVO 4 and a divalent copper compound.
- an antiviral composition that exhibits excellent antiviral properties in bright and dark places is obtained with the contained antiviral composition. be able to.
- the inorganic compound of the present invention is not particularly limited as long as it can support BiVO 4 .
- Preferred inorganic compounds include, for example, oxides, nitrides, sulfides, carbides and alloys, and more preferred compounds include oxides and nitrides.
- Preferred oxides include, for example, silica (SiO 2 ), alumina (Al 2 O 3 ), zirconia (ZrO 2 ), zeolite, titanium oxide (TiO 2 ), sodium titanate (NaTiO 3 , Na 2 Ti 6 O 13).
- barium titanate BaTiO 3
- strontium titanate SrTiO 3
- zinc oxide ZnO
- tungsten oxide WO 3
- potassium niobate K 2 NbO 3 , K 4 Nb 6 O 17 etc.
- iron oxide Fe 2 O 3
- tantalum oxide Ta 2 O 5
- tin oxide SnO 2
- nickel oxide NiO
- ruthenium oxide RuO 2
- cerium oxide CeO 2
- Preferred nitrides include, for example, boron nitride (BN), aluminum nitride (AlN), silicon nitride (Si 3 N 4 ), titanium nitride (TiN), and the like.
- Preferred sulfides include, for example, cadmium sulfide (CdS) and molybdenum sulfide (MoS 2 ).
- Preferred carbides include, for example, silicon carbide (SiC), tungsten carbide (WC), titanium carbide (TiC), and boron carbide (B 4 C).
- a preferred alloy is, for example, indium lead (InPb). These can be used individually by 1 type or in mixture of 2 or more types.
- More preferred oxides are titanium oxide (TiO 2 ) and iron oxide (Fe 2 O 3 ), and a more preferred nitride is boron nitride (BN). These can be used individually by 1 type or in mixture of 2 or more types. That is, the inorganic compound is more preferably one or more selected from the group consisting of titanium oxide, zeolite, and iron oxide.
- the inorganic compound is titanium oxide
- examples of such titanium oxide include anatase-type titanium oxide, rutile-type titanium oxide, and brookite-type titanium oxide.
- the specific surface area of the inorganic compound used in the present invention is preferably 3 to 1000 m 2 / g, more preferably 50 to 500 m 2 / g, and still more preferably 100 to 300 m 2 / g.
- the specific surface area of the inorganic compound is 3 to 1000 m 2 / g or less, handling of the antiviral composition becomes easy in application of the antiviral composition such as coating of the antiviral composition.
- the specific surface area is a specific surface area measured by a BET three-point method by nitrogen adsorption.
- the average primary particle diameter (nm) in terms of BET can be determined from the BET specific surface area using the following formula.
- Average primary particle diameter (nm) 6000 / (S (m 2 / g) ⁇ ⁇ (g / cm 3 )
- S is the BET specific surface area
- ⁇ is the density.
- Density The ([rho), rutile type titanium oxide 4.3 g / cm 3, anatase type titanium oxide 3.9 g / cm 3, boron nitride 3.5 g / cm 3, the zeolite is 0.90 g / cm 3, Iron oxide is calculated using a value of 5.2 g / cm 3 .
- BiVO 4 of the present invention exhibits high photocatalytic activity in the visible light region.
- BiVO 4 includes those produced by the solid phase method and those produced by the liquid phase method, and any of them can be used in the antiviral composition of the present invention.
- the particle size of BiVO 4 itself is reduced. Since the particle size of BiVO 4 is reduced, it is possible to reduce the rate of BiVO 4 antiviral composition, the color of the antiviral composition can vary from bright yellow to pale yellow . Thereby, the antiviral composition can be applied to various fields (for example, hospital interior materials) where it is not preferable to exhibit a bright yellow color.
- the particle size of the supported BiVO 4 is preferably 1 nm to 5 ⁇ m, more preferably 5 nm to 1 ⁇ m or less, further preferably 5 nm to 500 nm or less, and particularly preferably 5 nm to 300 nm or less.
- the particle size of BiVO 4 is 1 nm or more, the crystallinity is high, and the antiviral properties of the antiviral composition in the light and dark places become more excellent. Further, when the particle size of BiVO 4 is 5 ⁇ m or less, the frequency of contact of the virus with the surface of the antiviral composition increases, and the antiviral properties of the antiviral composition in the light and dark places become more excellent. .
- the particle size of BiVO 4 is a value obtained by observation of reflected electron images.
- the measuring device “Super High Performance Scanning Electron Microscope S-5500” manufactured by Hitachi, Ltd. was used.
- the particle size was measured as follows. Thirty BiVO 4 particles were observed with a reflected electron image, and the minimum and maximum values were taken as the particle diameter. For example, when particles of 100, 40, 60, 130,..., 80 nm are observed, the particle size of BiVO 4 particles is set to 40 to 130 nm.
- the mass of BiVO 4 is preferably 1 to 20 parts by mass, more preferably 2 to 15 parts by mass, and further preferably 3 to 10 parts by mass with respect to 100 parts by mass of the inorganic compound.
- the mass of BiVO 4 is 1 to 20 parts by mass with respect to 100 parts by mass of the photocatalytic titanium oxide particles, the antiviral properties in the bright and dark areas of the antiviral composition are improved, and It can suppress that a viral composition has a bright yellow color.
- the ratio of Bi element in a composition can be made small and it is economical.
- Examples of the method for supporting BiVO 4 on an inorganic compound include a solid phase method, a liquid phase method, and a mechanical ironing method.
- the divalent copper compound of the present invention is a copper compound having a copper valence of 2.
- a divalent copper compound alone does not exhibit antiviral properties in light and dark places.
- an inorganic compound carrying BiVO 4 antiviral properties in light and dark places are expressed in the divalent copper compound.
- the divalent copper compound is not particularly limited as long as it is a copper compound having a copper valence of 2.
- the divalent copper compound is (a) the following general formula (1): Cu 2 (OH) 3 X (1) (In the formula, X represents an anion) (B) Divalent copper halide, (c) Divalent copper inorganic acid salt, (d) Divalent copper organic acid salt, (e) Cupric oxide , (F) copper sulfide, (g) copper (II) azide and (h) one or more selected from the group consisting of copper silicate.
- More preferable X in the general formula (1) is halogen such as Cl, Br and I, conjugate base of carboxylic acid such as CH 3 COO, conjugate base of inorganic acid such as NO 3 and (SO 4 ) 1/2 and OH
- halogen such as Cl, Br and I
- conjugate base of carboxylic acid such as CH 3 COO
- conjugate base of inorganic acid such as NO 3 and (SO 4 ) 1/2 and OH
- Any one selected from the group consisting of Further preferred X in the general formula (1) is one selected from the group consisting of Cl, CH 3 COO, NO 3 , (SO 4 ) 1/2 and OH.
- the divalent copper halide is one or more selected from the group consisting of copper chloride, copper fluoride and copper bromide.
- a more preferred divalent copper halide is copper chloride.
- inorganic salts of divalent copper are copper sulfate, copper nitrate, copper iodate, copper perchlorate, copper oxalate, copper tetraborate, copper ammonium sulfate, copper amidosulfate, copper ammonium chloride, pyrroline One or more selected from the group consisting of acid copper and copper carbonate.
- a more preferred inorganic salt of divalent copper is copper sulfate.
- divalent copper carboxylate More preferable organic salt of divalent copper is divalent copper carboxylate.
- Preferred divalent copper carboxylates include copper formate, copper acetate, copper propionate, copper butyrate, copper valerate, copper caproate, copper enanthate, copper caprylate, copper pelargonate, copper caprate, misty acid Copper, copper palmitate, copper margarate, copper stearate, copper oleate, copper lactate, copper malate, copper citrate, copper benzoate, copper phthalate, copper isophthalate, copper terephthalate, copper salicylate, melittic acid Copper, copper oxalate, copper malonate, copper succinate, copper glutarate, copper adipate, copper fumarate, copper glycolate, copper glycerate, copper gluconate, copper tartrate, copper acetylacetone, copper ethylacetoacetate, isoyoshichi Copper herbate, copper ⁇ -resorcylate, copper di
- divalent copper compounds are selected from the group consisting of oxine copper, acetylacetone copper, ethyl acetoacetate copper, trifluoromethane sulfonate copper, phthalocyanine copper, copper ethoxide, copper isopropoxide, copper methoxide and dimethyldithiocarbamate copper. 1 type or 2 types or more are mentioned.
- the divalent copper compound of the present invention is preferably (a) a hydroxyl group-containing divalent copper compound represented by the general formula (1), (b) a divalent copper halide, and (c) an inorganic divalent copper. Acid salt or (d) an organic acid salt of divalent copper. Moreover, since there are few impurities and cost does not start, the divalent copper compound of this invention is still more preferably a hydroxyl group-containing divalent copper compound represented by the above general formula (1).
- the (a) hydroxyl group-containing divalent copper compound represented by the general formula (1) may be an anhydride or a hydrate.
- the mass of copper element (the mass of Cu) in the divalent copper compound contained in the antiviral composition of the present invention is preferably 0.01-20 with respect to 100 parts by mass of the total of the inorganic compound and BiVO 4. Parts by mass, more preferably 0.1 to 20 parts by mass, still more preferably 0.1 to 15 parts by mass, and particularly preferably 0.3 to 10 parts by mass.
- the copper element mass in the divalent copper compound is 0.01 parts by mass or more with respect to 100 parts by mass of the total of the inorganic compound and BiVO 4 , the antiviral properties and antibacterial properties in the bright and dark places are good Become.
- elemental copper mass in divalent copper compound and per 100 parts by weight of the total of the inorganic compound and BiVO 4 is 20 parts by mass or less
- the surface of the inorganic compounds bearing BiVO 4 are divalent copper compound It is prevented from being coated, the photocatalytic activity of the antiviral composition can be increased, and the virus can be inactivated with a small amount of the antiviral composition, which is economical.
- copper element mass in divalent copper compound on 100 parts by weight of the total of the inorganic compound and BiVO 4 may be calculated second source of divalent copper compound, a charge of the inorganic compound and BiVO 4.
- the divalent copper compound may be supported on an inorganic compound and / or BiVO 4 .
- the divalent copper compound may be dispersed in the inorganic compound and BiVO 4 without being supported on the inorganic compound and / or BiVO 4 .
- the antiviral composition of the present invention contains, as essential components, an inorganic compound carrying BiVO 4 and a divalent copper compound, but within the range not impairing the object of the present invention, An optional component may be contained.
- the total content of the inorganic compound carrying BiVO 4 and the divalent copper compound in the antiviral composition is preferably relative to the mass of the antiviral composition. Is 90% by mass or more, more preferably 95% by mass or more, still more preferably 99% by mass or more, and particularly preferably 100% by mass.
- the antiviral agent and photocatalyst of the present invention include the antiviral composition of the present invention. Thereby, the antiviral agent and photocatalyst of the present invention have excellent antiviral properties in bright and dark places.
- antiviral composition of the present invention may be used in a solid form such as fine powder and granules. In this case, for example, the antiviral composition of the present invention is used by filling a predetermined container.
- the antiviral composition of the present invention may be used in a usage form in which the antiviral composition of the present invention is contained on the surface and / or inside of a predetermined substrate. In general, the latter form of use is preferred.
- the base material include a single base material made of general members such as fibers, metals, ceramics, and glass, and a composite base material made of two or more members of the above-described members.
- the substrate is not limited to these.
- the antiviral composition of the present invention may be contained in a coating agent such as floor polish that can be peeled off by an appropriate means. Further, the antiviral composition or the like of the present invention may be immobilized on a predetermined film, and the antiviral composition or the like of the present invention may be exposed on the surface of the continuous film. Alternatively, in the form of a film-like body produced by further forming a thin film such as the antiviral composition of the present invention by sputtering on the surface of a thin BiVO 4 formed on glass by sputtering, the antiviral of the present invention May be used. In addition, the antiviral composition of the present invention may be used in the form of a paint prepared using a solvent in which the antiviral composition of the present invention is dispersed.
- the antiviral composition or the like of the present invention is immobilized on the substrate surface using a general immobilizing means such as a binder, for example.
- a binder Materials that have been converted into materials.
- Either an organic binder or an inorganic binder can be used as a binder for immobilizing the antiviral composition of the present invention, but it is preferable to use an inorganic binder in order to avoid decomposition of the binder by a photocatalytic substance. .
- the kind of binder is not particularly limited.
- the inorganic binder include silica-based inorganic binders that are usually used for fixing the photocatalytic substance to the substrate surface.
- the organic binder include a polymer binder that can form a thin film by polymerization and solvent volatilization.
- the antiviral composition or the like of the present invention is dispersed in a resin to prepare a dispersion, and the dispersion is cured.
- the material obtained by is mentioned.
- the resin for dispersing the antiviral composition of the present invention both natural resins and synthetic resins can be used. Synthetic resins include, for example, acrylic resins, phenol resins, polyurethane resins, acrylonitrile / styrene copolymer resins, acrylonitrile / butadiene / styrene copolymer (ABS) resins, polyester resins, and epoxy resins. It is not limited.
- the antiviral composition of the present invention can be used in the presence of arbitrary light or in the dark. Further, the antiviral composition or the like of the present invention can be used in the presence of water (for example, in water and seawater), in a dry state (for example, in a low humidity state in winter, etc.), in a high humidity state, or in an organic matter. Even in the presence of coexistence, it has excellent virus inactivating properties and can inactivate viruses continuously.
- the antiviral composition of the present invention can be placed on walls, floors, ceilings, and the like.
- any object such as hospitals and factories such as buildings, machine tools, measuring devices, interiors and parts of electrical appliances (for example, interiors of refrigerators, washing machines, dishwashers, etc. and filters of air cleaners)
- the antiviral composition of the present invention can be applied to the product.
- Examples of the dark place include, but are not limited to, the inside of a machine, a refrigerator storage room, and a hospital facility (a waiting room, an operating room, etc.) that becomes a dark place at night or when not in use.
- an air cleaning machine As a countermeasure against influenza, an air cleaning machine has been proposed in which a ceramic filter or a non-woven filter is coated with titanium oxide and a light source for irradiating the filter with ultraviolet light is incorporated.
- a ceramic filter or a non-woven filter is coated with titanium oxide and a light source for irradiating the filter with ultraviolet light is incorporated.
- an ultraviolet light source is not necessary, thereby reducing the cost of the air cleaner and increasing the safety of the air cleaner. it can.
- the present invention provides a virus inactivation method, wherein a virus is inactivated using the antiviral composition of the present invention, the antiviral agent of the present invention or the photocatalyst of the present invention.
- a virus is inactivated using the antiviral composition of the present invention, the antiviral agent of the present invention or the photocatalyst of the present invention.
- the antiviral composition of the present invention exhibits antiviral properties, it is possible to inactivate viruses using the antiviral composition of the present invention.
- the antiviral agent and photocatalyst of this invention contain the antiviral composition of this invention, a virus can be inactivated using the antiviral agent or photocatalyst of this invention.
- Example 1 Suspension is prepared by suspending 10.00 g of rutile type titanium oxide (manufactured by Showa Denko Ceramics Co., Ltd.) in 300 mL of distilled water, and the pH of the suspension is adjusted to 1.3 with 5 M HNO 3 aqueous solution. did. Next, 5M HNO 3 in which 0.7520 g of Bi (NO 3 ) 3 .5H 2 O (manufactured by Kanto Chemical Co., Ltd.) and 0.1815 g of NH 4 VO 3 (manufactured by Kanto Chemical Co., Ltd.) were dissolved respectively.
- rutile type titanium oxide manufactured by Showa Denko Ceramics Co., Ltd.
- 5M HNO 3 in which 0.7520 g of Bi (NO 3 ) 3 .5H 2 O (manufactured by Kanto Chemical Co., Ltd.) and 0.1815 g of NH 4 VO 3 (manufactured by Kanto Chemical Co., Ltd.) were dissolved respectively.
- the solution was prepared and poured into the suspension in the order of Bi (NO 3) 3 ⁇ 5H HNO 3 solution of 2 O, HNO 3 solution of NH 4 VO 3. Thereafter, 10.00 g of urea (manufactured by Kanto Chemical Co., Inc.) was put into the suspension, heated to a temperature of 80 ° C. on a hot stirrer, and maintained at a temperature of 80 ° C. for 8 hours. The obtained suspension was filtered and dried to obtain BiVO 4 / rutile titanium oxide powder (supporting 5 parts by mass of BiVO 4 with respect to rutile titanium oxide).
- Example 1 CuCl 2 .2H 2 O is hydrolyzed to Cu 2 (OH) 3 Cl.
- the pH of the suspension was measured using a pH meter (D-51, manufactured by Horiba, Ltd.).
- Example 2 A sample of Example 2 was prepared in the same manner as in Example 1 except that the rutile type titanium oxide was changed to anatase type titanium oxide (manufactured by Showa Denko Ceramics Co., Ltd.).
- Example 3 A sample of Example 3 was produced in the same manner as in Example 1 except that rutile titanium oxide was changed to BN (manufactured by Kanto Chemical Co., Inc.).
- Example 4 A sample of Example 4 was produced in the same manner as in Example 1 except that rutile titanium oxide was changed to zeolite (Union Showa Co., Ltd., trade name: ABSENT 3000).
- Example 5 A sample of Example 5 was produced in the same manner as in Example 1 except that the rutile titanium oxide was Fe 2 O 3 (manufactured by Kanto Chemical Co., Inc.).
- Example 6 Bi (NO 3) 3 ⁇ 5H 2 Bi (NO 3) use in fabricating HNO 3 solution prepared by dissolving O 3 ⁇ 5H 2 O in an amount and NH 4 VO 3 when fabricating a HNO 3 solution of
- a sample of Example 6 was produced in the same manner as in Example 1 except that the amount of NH 4 VO 3 used in 1 was reduced to one fifth of that in Example 1.
- Example 7 Bi (NO 3) 3 ⁇ 5H 2 Bi (NO 3) use in fabricating HNO 3 solution prepared by dissolving O 3 ⁇ 5H 2 O in an amount and NH 4 VO 3 when fabricating a HNO 3 solution of
- a sample of Example 7 was prepared in the same manner as in Example 1 except that the amount of NH 4 VO 3 used for the sample was doubled compared to Example 1.
- Comparative Example 4 A sample of Comparative Example 4 was prepared in the same manner as Comparative Example 3 except that the rutile titanium oxide was changed to anatase type titanium oxide (Showa Denko Ceramics Co., Ltd.).
- Comparative Example 5 A sample of Comparative Example 5 was prepared in the same manner as Comparative Example 3 except that BN (Kanto Chemical Co., Ltd.) was used as the rutile titanium oxide.
- Comparative Example 6 A sample of Comparative Example 6 was produced in the same manner as Comparative Example 3 except that rutile titanium oxide was changed to zeolite (Union Showa Co., Ltd., trade name: ABSENT 3000).
- Comparative Example 7 A sample of Comparative Example 7 was produced in the same manner as Comparative Example 3 except that the rutile type titanium oxide was Fe 2 O 3 (manufactured by Kanto Chemical Co., Inc.).
- the solution was prepared and poured into the suspension in the order of Bi (NO 3) 3 ⁇ 5H HNO 3 solution of 2 O, HNO 3 solution of NH 4 VO 3. Thereafter, 10.00 g of urea (manufactured by Kanto Chemical Co., Inc.) was put into the suspension, heated to a temperature of 80 ° C. on a hot stirrer, and maintained at a temperature of 80 ° C. for 8 hours.
- the sample of Comparative Example 8 was produced by filtering and drying the obtained suspension.
- compositions of the samples of Examples 1 to 7 and the samples of Comparative Examples 1 to 8 are shown in Table 1 below.
- “Abcent 3000” is a trade name of zeolite manufactured by Union Showa Co., Ltd.
- Cu 2 (OH) 3 Cl mass section is a parts by weight when converted into Cu with respect to 100 parts by mass of the total of the inorganic compound and BiVO 4.
- BET specific surface area The BET specific surface areas of rutile type titanium oxide (TiO 2 ), anatase type titanium oxide (TiO 2 ), boron nitride (BN), zeolite, and iron (III) oxide (Fe 2 O 3 ) are all manufactured by Mountec Co., Ltd. Using an automatic BET specific surface area measuring apparatus “Macsorb, HM model-1208”, measurement was performed in a nitrogen atmosphere by the BET three-point method.
- the average primary particle diameter (D BET ) (nm) is determined by the BET three-point method using a BET specific surface area S (titanium oxide (TiO 2 ), boron nitride (BN), zeolite, iron oxide (III) (Fe 2 O 3 )).
- m 2 / g) was measured and calculated from the following equation.
- Average primary particle diameter (nm) 6000 / (S (m 2 / g) ⁇ ⁇ (g / cm 3 )
- ⁇ represents the density (g / cm 3 ) of the oxide.
- Samples for Examples 1 to 7 and Comparative Examples 1 to 8 were applied on glass plates (50 mm ⁇ 50 mm ⁇ 1 mm) to prepare evaluation samples. By applying 2.5 mg of the samples of Examples 1 to 7 and Comparative Examples 3 to 8 on the glass plate, and separately applying 0.125 mg of the samples of Comparative Examples 1 and 2 on the glass plate. , the coating amount per unit area to prepare an evaluation sample respectively 1.0 g / m 2 and 0.05 g / m 2. In addition, although the application amount per unit area of Comparative Example 1 and Comparative Example 2 is small, since the inorganic compound is not contained in Comparative Example 1 and Comparative Example 2, the application amount per unit area of BiVO 4 1 to 7 and Comparative Examples 1 to 8 are all the same.
- a filter paper was laid in the deep petri dish, and a small amount of sterilized water was added.
- the sample for evaluation described above was placed on the filter paper.
- 1/500 NB was used to prepare a bacteriophage infectivity of about 6.7 ⁇ 10 6 to about 2.6 ⁇ 10 7 pfu / ml, and 100 ⁇ L of Q ⁇ phage (NBRC20012) suspension was dropped.
- a PET (polyethylene terephthalate) film was covered to bring the sample surface into contact with the phage.
- This deep petri dish covered with a glass plate was used as a measurement set. A plurality of similar measurement sets were prepared.
- a 15 W white fluorescent lamp manufactured by Panasonic Corporation, full white fluorescent lamp, FL15N
- an ultraviolet cut filter Naitto Resin Kogyo Co., Ltd., N-113
- a plurality of sets for measurement were allowed to stand at a position where the illuminance was 800 lux (illuminance meter: measured by IM-5 manufactured by Topcon Corporation).
- the phage concentration of the sample on the glass plate was measured after 5 minutes and 30 minutes from the start of light irradiation.
- the illuminance of the room at the time of measurement was set to be 200 lux or less.
- the elapsed time from the start of light irradiation was measured using a commercially available stopwatch.
- the phage concentration was measured by the following method.
- the sample on the glass plate was infiltrated into 9.9 ml of phage recovery solution (SCDLP medium) and shaken for 10 minutes with a shaker.
- This phage recovery solution was appropriately diluted with physiological saline containing peptone. 1 ml of the previously diluted solution is added to a mixture of 5.0 ⁇ 10 8 to 2.0 ⁇ 10 9 cells / ml E. coli (NBRC106373) culture solution and calcium-added LB soft agar medium. After mixing, this solution was spread on a calcium-added LB agar medium and cultured at 37 ° C. for 15 hours, and the number of phage plaques was visually measured.
- the phage concentration N was determined by multiplying the number of plaques obtained by the dilution factor of the phage recovery solution.
- the relative phage concentration (LOG (N / N 0 ) was determined from the initial phage concentration N 0 and the phage concentration N after a predetermined time. The smaller the value of LOG (N / N 0 ) (the greater the negative value), the better the antiviral properties of the sample.
- FIG. 1 A photograph of the reflected electron image of the sample of Example 1 is shown in FIG. 1, and a photograph of the reflected electron image of the sample of Example 5 is shown in FIG. 1 (a) and 2 (a) are photographs of reflected electron images at a magnification of 30000 times, and FIGS. 1 (b) and 2 (b) are photographs of reflected electron images at a magnification of 100000 times. is there.
- FIG. 1 and FIG. 2 it can be determined that a region that appears particularly bright in the reflected electron image is a region where Bi, which is a heavy element, is present. From the reflected electron image, BiVO 4 were found to have bonded to titanium oxide and iron oxide which is an inorganic compound, which than, BiVO 4 was found to be supported on an inorganic compound.
- Examples 1 to 7 were found to have a virus inactivation ability of 99.9% in a short period of 30 minutes when irradiated with visible light having an illuminance of 800 lux. From comparison between Examples 1 to 7 and Comparative Examples 1 and 2, it was found that even though the amount of BiVO 4 applied per unit area was the same, Examples 1 to 7 exhibited excellent antiviral properties. . Further, by an inorganic compound enters the antiviral composition, it was found that the yellow BiVO 4 is suppressed. From comparison between Examples 1 to 7 and Comparative Examples 3 to 8, it was found that the antiviral properties were significantly improved by BiVO 4 supported on an inorganic compound.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Materials Engineering (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Agronomy & Crop Science (AREA)
- Plant Pathology (AREA)
- Pest Control & Pesticides (AREA)
- Dentistry (AREA)
- Environmental Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Toxicology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Crystallography & Structural Chemistry (AREA)
- Catalysts (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Exhaust Gas Treatment By Means Of Catalyst (AREA)
Abstract
Description
[2]BiVO4の質量が、無機化合物の100質量部に対して1~20質量部である、上記[1]に記載の抗ウイルス性組成物。
[3]無機化合物は酸化物または窒化物である、上記[1]または[2]に記載の抗ウイルス性組成物。
[4]無機化合物は、酸化チタン、ゼオライトおよび酸化鉄からなる群から選択される1種または2種以上である、上記[3]に記載の抗ウイルス性組成物。
[5]2価銅化合物中の銅元素質量が、無機化合物およびBiVO4の合計の100質量部に対して0.01~20質量部である、上記[1]~[4]のいずれかに記載の抗ウイルス性組成物。
[6]2価銅化合物は、(a)下記一般式(1):
Cu2(OH)3X (1)
(式中、Xは陰イオンを示す)
で表される水酸基含有2価銅化合物、(b)2価銅のハロゲン化物、(c)2価銅の無機酸塩、(d)2価銅の有機酸塩、(e)酸化第二銅、(f)硫化銅、(g)アジ化銅(II)および(h)ケイ酸銅からなる群から選択される1種または2種以上である、上記[1]~[5]のいずれかに記載の抗ウイルス性組成物。
[7]一般式(1)のXが、ハロゲン、カルボン酸の共役塩基、無機酸の共役塩基およびOHからなる群から選択される1種または2種以上である、上記[6]に記載の抗ウイルス性組成物。
[8]Xは、Cl、CH3COO、NO3および(SO4)1/2からなる群から選択される1種である、上記[6]に記載の抗ウイルス性組成物。
[9](b)2価銅のハロゲン化物は、塩化銅、フッ化銅および臭化銅からなる群から選択される1種または2種以上である、上記[6]に記載の抗ウイルス性組成物。
[10](c)2価銅の無機酸塩は、硫酸銅、硝酸銅、ヨウ素酸銅、過塩素酸銅、シュウ酸銅、四ホウ酸銅、硫酸アンモニウム銅、アミド硫酸銅、塩化アンモニウム銅、ピロリン酸銅および炭酸銅からなる群から選択される1種または2種以上である、上記[6]に記載の抗ウイルス性組成物。
[11](d)2価銅の有機酸塩は2価銅のカルボン酸塩である、上記[6]に記載の抗ウイルス性組成物。
[12]2価銅化合物は一般式(1)で表される水酸基含有2価銅化合物である、上記[6]または[7]に記載の抗ウイルス性組成物。
[13]800ルクスの照度の可視光照射30分間で99.9%のウイルス不活化能力を有する上記[1]~[12]のいずれかに記載の抗ウイルス性組成物。
[14]上記[1]~[13]のいずれかに記載の抗ウイルス性組成物を含有する抗ウイルス剤。
[15]上記[1]~[13]のいずれかに記載の抗ウイルス性組成物を含有する光触媒。
[16]上記[1]~[13]のいずれかに記載の抗ウイルス性組成物、上記[14]に記載の抗ウイルス剤または上記[15]に記載の光触媒を用いてウイルスを不活化する、ウイルス不活性化方法。
本発明の抗ウイルス性組成物は、BiVO4を担持した無機化合物と、2価銅化合物とを含有する組成物である。BiVO4を担持した無機化合物と、2価銅化合物とを組み合わせることにより、含有する抗ウイルス性組成物で、明所および暗所において優れた抗ウイルス性を発現する、抗ウイルス性組成物を得ることができる。
本発明の無機化合物は、BiVO4を担持することができれば特に限定されない。好ましい無機化合物には、たとえば、酸化物、窒化物、硫化物、炭化物および合金などが挙げられ、より好ましい化合物には、酸化物および窒化物が挙げられる。好ましい酸化物には、たとえば、シリカ(SiO2)、アルミナ(Al2O3)、ジルコニア(ZrO2)、ゼオライト、酸化チタン(TiO2)、チタン酸ナトリウム(NaTiO3、Na2Ti6O13など)、チタン酸バリウム(BaTiO3)、チタン酸ストロンチウム(SrTiO3)、酸化亜鉛(ZnO)、酸化タングステン(WO3)、ニオブ酸カリウム(K2NbO3、K4Nb6O17など)、酸化鉄(Fe2O3)、酸化タンタル(Ta2O5)、酸化スズ(SnO2)、酸化ニッケル(NiO)、酸化ルテニウム(RuO2)および酸化セリウム(CeO2)などが挙げられる。好ましい窒化物には、たとえば、窒化ホウ素(BN)、窒化アルミニウム(AlN)、窒化ケイ素(Si3N4)および窒化チタン(TiN)などが挙げられる。好ましい硫化物には、たとえば、硫化カドミニウム(CdS)および硫化モリブデン(MoS2)などが挙げられる。好ましい炭化物には、たとえば、炭化ケイ素(SiC)、炭化タングステン(WC)、炭化チタン(TiC)および炭化ホウ素(B4C)などが挙げられる。好ましい合金は、たとえば、インジウム鉛(InPb)などである。これらは、1種単独で、または2種以上を混合して使用することができる。より好ましい酸化物は、酸化チタン(TiO2)および酸化鉄(Fe2O3)であり、より好ましい窒化物は窒化ホウ素(BN)である。これらは、1種単独で、または2種以上を混合して使用することができる。すなわち、無機化合物は、より好ましくは、酸化チタン、ゼオライトおよび酸化鉄からなる群から選択される1種または2種以上である。
平均一次粒子径(nm)=6000/(S(m2/g)×ρ(g/cm3)
ここで、SはBET比表面積であり、ρは密度である。密度(ρ)としては、ルチル型酸化チタンは4.3g/cm3、アナターゼ型酸化チタンは3.9g/cm3、窒化ホウ素は3.5g/cm3、ゼオライトは0.90g/cm3、酸化鉄は5.2g/cm3の値を用いて計算する。
本発明のBiVO4は、可視光領域で高い光触媒活性を示す。BiVO4には、固相法で製造されたものと液相法で製造されたものとがあり、本発明の抗ウイルス性組成物に、そのいずれを用いることができる。BiVO4には、たとえば、特開2001-2419号公報に記載のBiVO4の製造方法により製造されたものおよび特開2004-24936号公報に記載のBiVO4の製造方法により製造されたものなどが挙げられる。
本発明の2価銅化合物は、銅の価数が2である銅化合物である。2価銅化合物は単独では、明所および暗所における抗ウイルス特性を示さない。しかし、驚くことに、BiVO4を担持した無機化合物と組み合わせることにより、明所および暗所における抗ウイルス特性が2価銅化合物に発現する。2価銅化合物は、銅の価数が2である銅化合物であればとくに限定されない。たとえば、2価銅化合物は、(a)下記一般式(1):
Cu2(OH)3X (1)
(式中、Xは陰イオンを示す)
で表される水酸基含有2価銅化合物、(b)2価銅のハロゲン化物、(c)2価銅の無機酸塩、(d)2価銅の有機酸塩、(e)酸化第二銅、(f)硫化銅、(g)アジ化銅(II)および(h)ケイ酸銅からなる群から選択される1種または2種以上である。
本発明の抗ウイルス剤および光触媒は本発明の抗ウイルス性組成物を含む。これにより、本発明の抗ウイルス剤および光触媒は、明所および暗所において優れた抗ウイルス特性を有する。
本発明の抗ウイルス性組成物、抗ウイルス剤および光触媒(以下、「本発明の抗ウイルス性組成物等」ということがある)の使用形態はとくに限定されない。たとえば、本発明の抗ウイルス性組成物等を、微粉末および顆粒などの固体状の形態で使用してもよい。この場合、たとえば、本発明の抗ウイルス性組成物等を所定の容器に充填して使用する。または、所定の基材の表面および/または内部に本発明の抗ウイルス性組成物等を含ませる使用形態で、本発明の抗ウイルス性組成物等を使用してもよい。一般的には、後者の使用形態が好ましい。なお、上記の基材には、たとえば、繊維、金属、セラミックおよびガラスなどの一般的な部材からなる単一基材、ならびに上述の部材の2種以上の部材からなる複合基材が挙げられる。しかし、基材はこれらに限定されない。
本発明は、本発明の抗ウイルス性組成物、本発明の抗ウイルス剤または本発明の光触媒を用いてウイルスを不活化する、ウイルス不活性化方法を提供する。上述したように、本発明の抗ウイルス性組成物は抗ウイルス性を発現するので、本発明の抗ウイルス性組成物を用いてウイルスを不活化できる。また、本発明の抗ウイルス剤および光触媒は本発明の抗ウイルス性組成物を含有するので、本発明の抗ウイルス剤または光触媒を用いてウイルスを不活化できる。
蒸留水300mLに10.00gのルチル型酸化チタン(昭和電工セラミックス(株)製)を懸濁させて懸濁液を作製し、5MのHNO3水溶液で懸濁液のpHを1.3に調整した。次に、0.7520gのBi(NO3)3・5H2O(関東化学(株)製)および0.1815gのNH4VO3(関東化学(株)製)をそれぞれ溶解した5MのHNO3溶液を準備し、Bi(NO3)3・5H2Oを溶解したHNO3溶液、NH4VO3を溶解したHNO3溶液の順で懸濁液中に投入した。その後、10.00gの尿素(関東化学(株)製)を懸濁液中に投入し、ホットスターラー上で80℃の温度に加熱し、80℃の温度で8時間保持した。得られた懸濁液をろ過、乾燥することで、BiVO4/ルチル型酸化チタン粉末(ルチル型酸化チタンに対して5質量部のBiVO4担持)を得た。
ルチル型酸化チタンをアナターゼ型酸化チタン(昭和電工セラミックス(株)製)としたこと以外は実施例1と同様の方法で実施例2の試料を作製した。
ルチル型酸化チタンをBN(関東化学(株)製)としたこと以外は実施例1と同様の方法で実施例3の試料を作製した。
ルチル型酸化チタンをゼオライト(ユニオン昭和(株)製、商品名:アブセント3000)としたこと以外は実施例1と同様の方法で実施例4の試料を作製した。
ルチル型酸化チタンをFe2O3(関東化学(株)製)としたこと以外は実施例1と同様の方法で実施例5の試料を作製した。
Bi(NO3)3・5H2Oを溶解したHNO3溶液を作製するときに使用するBi(NO3)3・5H2Oの量およびNH4VO3を溶解したHNO3溶液を作製するときに使用するNH4VO3の量を、実施例1に比べて5分の1にしたこと以外は実施例1と同様の方法で実施例6の試料を作製した。
Bi(NO3)3・5H2Oを溶解したHNO3溶液を作製するときに使用するBi(NO3)3・5H2Oの量およびNH4VO3を溶解したHNO3溶液を作製するときに使用するNH4VO3の量を、実施例1に比べて2倍にしたこと以外は実施例1と同様の方法で実施例7の試料を作製した。
蒸留水300mLを5MのHNO3水溶液で1.3のpHに調整した。次に、0.7520gのBi(NO3)3・5H2O(関東化学(株)製)および0.1815gのNH4VO3(関東化学(株)製)をそれぞれ溶解した5MのHNO3溶液を準備し、Bi(NO3)3・5H2Oを溶解したHNO3溶液、NH4VO3を溶解したHNO3溶液の順で、pHを調整した蒸留水中に投入して懸濁液を作製した。その後、10.00gの尿素(関東化学(株)製)を懸濁液中に投入し、ホットスターラー上で80℃の温度に加熱し、80℃の温度で8時間保持した。得られた懸濁液をろ過、乾燥することで、比較例1の試料(BiVO4粉末)を得た。
蒸留水100mLに比較例1で得られた6gの粉末を懸濁させ、0.0805g(BiVO4の100質量部に対して銅で0.5質量部)のCuCl2・2H2O(関東化学(株)製)を添加して、10分攪拌して懸濁液を作製した。懸濁液のpHが10になるように、1mol/Lの水酸化ナトリウム(関東化学(株)製)水溶液を添加し、30分間攪拌混合を行ってスラリーを得た。このスラリーをろ過し、得られた粉体を純水で洗浄し、80℃で乾燥し、ミキサーで解砕し、比較例2の試料を得た。
蒸留水100mLに6gのルチル型酸化チタン(昭和電工セラミックス(株)製)を懸濁させて懸濁液を作製し、0.0805g(ルチル型酸化チタン100質量部に対して銅換算で0.5質量部)のCuCl2・2H2O(関東化学(株)製)を懸濁液に添加して、懸濁液を10分攪拌した。懸濁液のpHが10になるように、1mol/Lの水酸化ナトリウム(関東化学(株)製)水溶液を懸濁液に添加し、懸濁液を30分間攪拌混合してスラリーを得た。このスラリーをろ過し、得られた粉体を純水で洗浄し、80℃で乾燥し、ミキサーで解砕し、比較例3の試料を得た。
ルチル型酸化チタンをアナターゼ型酸化チタン(昭和電工セラミックス(株)製)としたこと以外は比較例3と同様の方法で比較例4の試料を作製した。
ルチル型酸化チタンをBN(関東化学(株)製)としたこと以外は比較例3と同様の方法で比較例5の試料を作製した。
ルチル型酸化チタンをゼオライト(ユニオン昭和(株)製、商品名:アブセント3000)としたこと以外は比較例3と同様の方法で比較例6の試料を作製した。
ルチル型酸化チタンをFe2O3(関東化学(株)製)としたこと以外は比較例3と同様の方法で比較例7の試料を作製した。
蒸留水300mLに10.00gのルチル型酸化チタン(昭和電工セラミックス(株)製)を懸濁させて懸濁液を作製し、5MのHNO3水溶液で懸濁液のpHを1.3に調整した。次に、0.7520gのBi(NO3)3・5H2O(関東化学(株)製)および0.1815gのNH4VO3(関東化学(株)製)をそれぞれ溶解した5MのHNO3溶液を準備し、Bi(NO3)3・5H2Oを溶解したHNO3溶液、NH4VO3を溶解したHNO3溶液の順で懸濁液中に投入した。その後、10.00gの尿素(関東化学(株)製)を懸濁液中に投入し、ホットスターラー上で80℃の温度に加熱し、80℃の温度で8時間保持した。得られた懸濁液をろ過、乾燥することで、比較例8の試料を作製した。
なお、表1において「アブセント3000」は、ユニオン昭和(株)製のゼオライトの商品名である。また、Cu2(OH)3Clの質量部は、無機化合物およびBiVO4の合計の100質量部に対してCuに換算したときの質量部である。
以上のように作製した実施例1~7および比較例1~8の試料について、以下の評価を行った。
実施例1~5の試料および比較例1および2の試料についてX線回折を行い、試料中に存在する、BiおよびVからなる化合物は、すべて単斜晶系のBiVO4であるか否かを調べた。測定装置にはPANalytical社製の「X’pertPRO」を用い、銅ターゲットを使用し、Cu-Kα1線を用いて、管電圧45kV、管電流40mA、測定範囲2θ=20~100deg、サンプリング幅0.0167deg、および走査速度3.3deg/minの条件でX線回折測定を行った。
実施例1および5の試料の反射電子像観察を行い、BiVO4が無機化合物に担持されているか否かを調べた。測定装置には日立(株)製「超高分解能走査電子顕微鏡S-5500」を使用した。
ルチル型酸化チタン(TiO2)、アナターゼ型酸化チタン(TiO2)、窒化ホウ素(BN)、ゼオライト、酸化鉄(III)(Fe2O3)のBET比表面積は、(株)マウンテック製の全自動BET比表面積測定装置「Macsorb,HM model-1208」を用いて、BET3点法により窒素雰囲気下で測定した。
平均一次粒子径(DBET)(nm)は、BET3点法により、酸化チタン(TiO2)、窒化ホウ素(BN)、ゼオライト、酸化鉄(III)(Fe2O3)のBET比表面積S(m2/g)を測定し、下式より算出した。
平均一次粒子径(nm)=6000/(S(m2/g)×ρ(g/cm3)
ここでρは上記酸化物の密度(g/cm3)を示す。具体的には、密度としては、ルチル型酸化チタンは4.3g/cm3、アナターゼ型酸化チタンは3.9g/cm3、窒化ホウ素は3.5g/cm3、ゼオライトは0.90g/cm3、酸化鉄は5.2g/cm3の値を用いて計算した。
実施例1~7の試料および比較例1~8の試料の抗ウイルス特性は、バクテリオファージを用いたモデル実験により以下の方法で確認した。なお、バクテリオファージに対する不活化能を抗ウイルス特性のモデルとして利用する方法は、たとえばAppl.Microbiol Biotechnol.,79,pp.127-133(2008)に記載されており、この方法により信頼性のある結果が得られることが知られている。また本測定はJIS R 1706を基礎としている。
測定用セットを暗所に置き、光源から光を照射しなかったこと以外は上記の(明所における抗ウイルス特性の評価:LOG(N/N0)の測定)と同様の測定を行った。なお、LOG(N/N0)の値が小さいほど(マイナスの値が大きいほど)、試料の抗ウイルス特性は優れている。
実施例1~7および比較例1~8の試料の色を目視で観察した。
(X線回折)
実施例1~5および比較例1、2の試料中に存在するBiおよびVからなる化合物は、すべて単斜晶系のBiVO4であることがわかった。
実施例1の試料の反射電子像の写真を図1に、実施例5の試料の反射電子像の写真を図2にそれぞれ示す。図1(a)および図2(a)は、30000倍の倍率の反射電子像の写真であり、図1(b)および図2(b)は、100000倍の倍率の反射電子像の写真である。図1および図2において、反射電子像でとくに明るく見える領域は重元素であるBiが存在している領域であると判断できる。この反射電子像から、BiVO4は、無機化合物である酸化チタンおよび酸化鉄に接合していることがわかり、これより、BiVO4は無機化合物に担持されていることがわかった。
可視光照射下における抗ウイルス特性の評価結果を以下の表2に示す。
暗所における抗ウイルス特性の評価結果を以下の表2に示す。
実施例1~7および比較例1~8の試料の色の観察結果を以下の表2に示す。
Claims (16)
- BiVO4を担持した無機化合物と、2価銅化合物とを含有する抗ウイルス性組成物。
- 前記BiVO4の質量が、前記無機化合物の100質量部に対して1~20質量部である、請求項1に記載の抗ウイルス性組成物。
- 前記無機化合物は酸化物または窒化物である、請求項1または2に記載の抗ウイルス性組成物。
- 前記無機化合物は、酸化チタン、ゼオライトおよび酸化鉄からなる群から選択される1種または2種以上である、請求項3に記載の抗ウイルス性組成物。
- 前記2価銅化合物中の銅元素質量が、前記無機化合物および前記BiVO4の合計の100質量部に対して0.01~20質量部である、請求項1~4のいずれか1項に記載の抗ウイルス性組成物。
- 前記2価銅化合物は、(a)下記一般式(1):
Cu2(OH)3X (1)
(式中、Xは陰イオンを示す)
で表される水酸基含有2価銅化合物、(b)2価銅のハロゲン化物、(c)2価銅の無機酸塩、(d)2価銅の有機酸塩、(e)酸化第二銅、(f)硫化銅、(g)アジ化銅(II)および(h)ケイ酸銅からなる群から選択される1種または2種以上である、請求項1~5のいずれか1項に記載の抗ウイルス性組成物。 - 一般式(1)のXが、ハロゲン、カルボン酸の共役塩基、無機酸の共役塩基およびOHからなる群から選択される1種または2種以上である、請求項6に記載の抗ウイルス性組成物。
- Xが、Cl、CH3COO、NO3および(SO4)1/2からなる群から選択される1種である、請求項6に記載の抗ウイルス性組成物。
- (b)2価銅のハロゲン化物は、塩化銅、フッ化銅および臭化銅からなる群から選択される1種または2種以上である、請求項6に記載の抗ウイルス性組成物。
- (c)2価銅の無機酸塩は、硫酸銅、硝酸銅、ヨウ素酸銅、過塩素酸銅、シュウ酸銅、四ホウ酸銅、硫酸アンモニウム銅、アミド硫酸銅、塩化アンモニウム銅、ピロリン酸銅および炭酸銅からなる群から選択される1種または2種以上である、請求項6に記載の抗ウイルス性組成物。
- (d)2価銅の有機酸塩は2価銅のカルボン酸塩である、請求項6に記載の抗ウイルス性組成物。
- 2価銅化合物は一般式(1)で表される水酸基含有2価銅化合物である、請求項6または7に記載の抗ウイルス性組成物。
- 800ルクスの照度の可視光照射30分間で99.9%のウイルス不活化能力を有する請求項1~12のいずれか1項に記載の抗ウイルス性組成物。
- 請求項1~13のいずれか1項に記載の抗ウイルス性組成物を含有する抗ウイルス剤。
- 請求項1~13のいずれか1項に記載の抗ウイルス性組成物を含有する光触媒。
- 請求項1~13のいずれか1項に記載の抗ウイルス性組成物、請求項14に記載の抗ウイルス剤または請求項15に記載の光触媒を用いてウイルスを不活化する、ウイルス不活性化方法。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201480072959.4A CN105899077A (zh) | 2014-02-20 | 2014-11-20 | 抗病毒性组合物、抗病毒剂、光催化剂以及病毒灭活方法 |
KR1020167015783A KR20160086906A (ko) | 2014-02-20 | 2014-11-20 | 항바이러스성 조성물, 항바이러스제, 광촉매 및 바이러스 불활성화 방법 |
JP2016503943A JPWO2015125367A1 (ja) | 2014-02-20 | 2014-11-20 | 抗ウイルス性組成物、抗ウイルス剤、光触媒およびウイルス不活性化方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014-030207 | 2014-02-20 | ||
JP2014030207 | 2014-02-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015125367A1 true WO2015125367A1 (ja) | 2015-08-27 |
Family
ID=53877896
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2014/080808 WO2015125367A1 (ja) | 2014-02-20 | 2014-11-20 | 抗ウイルス性組成物、抗ウイルス剤、光触媒およびウイルス不活性化方法 |
Country Status (5)
Country | Link |
---|---|
JP (1) | JPWO2015125367A1 (ja) |
KR (1) | KR20160086906A (ja) |
CN (1) | CN105899077A (ja) |
TW (1) | TW201608980A (ja) |
WO (1) | WO2015125367A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018058826A (ja) * | 2016-10-06 | 2018-04-12 | 大阪ガスケミカル株式会社 | 抗ウイルス剤 |
JPWO2017150063A1 (ja) * | 2016-03-01 | 2019-01-24 | 東亞合成株式会社 | 抗ウイルス剤、コーティング組成物、樹脂組成物及び抗ウイルス製品 |
CN110560142A (zh) * | 2019-10-09 | 2019-12-13 | 桂林理工大学 | 一种光催化复合薄膜及其制备方法和应用 |
WO2022125797A1 (en) * | 2020-12-09 | 2022-06-16 | Sintx Technologies, Inc. | Nitride based antipathogenic compositions and devices and methods of use thereof |
JP7396236B2 (ja) | 2020-08-31 | 2023-12-12 | Toto株式会社 | 可視光応答型光触媒 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110297023B (zh) * | 2019-07-09 | 2021-05-28 | 济南大学 | 一种检测降钙素原电化学催化协助的自增强光电化学免疫传感器的制备方法及应用 |
CN111359642B (zh) * | 2020-03-17 | 2021-06-11 | 北京大学 | 一种半导体广谱杀菌抗病毒复合材料和制备方法和制备方法 |
CN114747593B (zh) * | 2022-04-06 | 2023-06-23 | 湖南农业大学 | 一种MXene-氧化锌纳米复合材料及其制备方法和应用其制得的可循环疏水抗菌材料 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004330047A (ja) * | 2003-05-06 | 2004-11-25 | Univ Kanazawa | 内分泌撹乱物質光分解用金属又は金属酸化物担持型BiVO4光触媒 |
WO2011048128A2 (de) * | 2009-10-22 | 2011-04-28 | Basf Se | Photokatalysator mit erhöhter tageslichtaktivität |
JP2011136984A (ja) * | 2009-12-01 | 2011-07-14 | Sumitomo Chemical Co Ltd | 抗ウイルス剤およびそれを用いた抗ウイルス剤機能製品 |
JP2013166705A (ja) * | 2010-12-22 | 2013-08-29 | Univ Of Tokyo | ウイルス不活化剤 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3790189B2 (ja) * | 2002-06-21 | 2006-06-28 | 独立行政法人科学技術振興機構 | 可視光応答性BiVO4微粉末の新規合成法、該BiVO4微粉末からなる光触媒および該光触媒を用いた浄化方法 |
JP4208666B2 (ja) * | 2003-07-18 | 2009-01-14 | エスケー化研株式会社 | バナジン酸ビスマス微粒子の製造方法 |
JP4646210B2 (ja) * | 2005-02-24 | 2011-03-09 | 多木化学株式会社 | ファージ・ウイルスの不活性化剤 |
CN101402043B (zh) * | 2008-10-30 | 2011-04-27 | 大连理工大学 | 一种利用可见光光催化净化材料的空气净化方法 |
BR112012026077B1 (pt) * | 2010-04-16 | 2024-01-16 | Treibacher Industrie Ag | Composições catalisadoras para redução catalítica seletiva de gases de escapamento, e seu processo de preparação |
CN102275989B (zh) * | 2011-05-26 | 2013-02-13 | 黑龙江大学 | 利用乙二胺四乙酸调制的水热过程合成大比表面积纳米钒酸铋的方法 |
CN102553604A (zh) * | 2011-12-19 | 2012-07-11 | 陕西科技大学 | 微波水热法对BiVO4光催化剂进行Cu2+掺杂改性的方法 |
CN102580721B (zh) * | 2011-12-19 | 2014-07-02 | 陕西科技大学 | 微波水热制备TiO2/BiVO4复合光催化剂的方法 |
US9210939B2 (en) * | 2011-12-22 | 2015-12-15 | Showa Denko K.K. | Copper-and-titanium-containing composition and production method therefor |
CN102600857A (zh) * | 2012-03-01 | 2012-07-25 | 浙江大学 | 一种碳球负载的CuO-BiVO4异质结复合光催化剂的制备方法 |
-
2014
- 2014-11-20 KR KR1020167015783A patent/KR20160086906A/ko not_active Application Discontinuation
- 2014-11-20 WO PCT/JP2014/080808 patent/WO2015125367A1/ja active Application Filing
- 2014-11-20 CN CN201480072959.4A patent/CN105899077A/zh active Pending
- 2014-11-20 JP JP2016503943A patent/JPWO2015125367A1/ja not_active Withdrawn
- 2014-11-26 TW TW103140994A patent/TW201608980A/zh unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004330047A (ja) * | 2003-05-06 | 2004-11-25 | Univ Kanazawa | 内分泌撹乱物質光分解用金属又は金属酸化物担持型BiVO4光触媒 |
WO2011048128A2 (de) * | 2009-10-22 | 2011-04-28 | Basf Se | Photokatalysator mit erhöhter tageslichtaktivität |
JP2011136984A (ja) * | 2009-12-01 | 2011-07-14 | Sumitomo Chemical Co Ltd | 抗ウイルス剤およびそれを用いた抗ウイルス剤機能製品 |
JP2013166705A (ja) * | 2010-12-22 | 2013-08-29 | Univ Of Tokyo | ウイルス不活化剤 |
Non-Patent Citations (1)
Title |
---|
WANG ET AL.: "Visible-light-driven photocatalytic inactivation of E. coli K-12 by bismuth vanadate nanotubes: Bactericidal performance and mechanism", ENVIRONMENTAL SCIENCE AND TECHNOLOGY, vol. V46, 2012, pages 4599 - 4606, XP055221207 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2017150063A1 (ja) * | 2016-03-01 | 2019-01-24 | 東亞合成株式会社 | 抗ウイルス剤、コーティング組成物、樹脂組成物及び抗ウイルス製品 |
JP2018058826A (ja) * | 2016-10-06 | 2018-04-12 | 大阪ガスケミカル株式会社 | 抗ウイルス剤 |
CN110560142A (zh) * | 2019-10-09 | 2019-12-13 | 桂林理工大学 | 一种光催化复合薄膜及其制备方法和应用 |
CN110560142B (zh) * | 2019-10-09 | 2022-03-22 | 桂林理工大学 | 一种光催化复合薄膜及其制备方法和应用 |
JP7396236B2 (ja) | 2020-08-31 | 2023-12-12 | Toto株式会社 | 可視光応答型光触媒 |
WO2022125797A1 (en) * | 2020-12-09 | 2022-06-16 | Sintx Technologies, Inc. | Nitride based antipathogenic compositions and devices and methods of use thereof |
Also Published As
Publication number | Publication date |
---|---|
CN105899077A (zh) | 2016-08-24 |
KR20160086906A (ko) | 2016-07-20 |
JPWO2015125367A1 (ja) | 2017-03-30 |
TW201608980A (zh) | 2016-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2015125367A1 (ja) | 抗ウイルス性組成物、抗ウイルス剤、光触媒およびウイルス不活性化方法 | |
JP5812488B2 (ja) | 抗菌抗ウイルス性組成物及びその製造方法 | |
WO2013094573A1 (ja) | 銅及びチタン含有組成物並びにその製造方法 | |
JP6040021B2 (ja) | 抗菌抗ウイルス性組成物及びその製造方法 | |
WO2016042913A1 (ja) | 抗菌・抗ウイルス性組成物、抗菌・抗ウイルス剤、光触媒および菌・ウイルス不活化方法 | |
JP5570006B2 (ja) | ウイルス不活化剤 | |
JP5904524B2 (ja) | ウイルス不活化剤 | |
JP2015059089A (ja) | 抗ウイルス性組成物、その製造方法およびウイルス不活性化方法 | |
JP2011190192A (ja) | 微生物不活化剤 | |
KR101767528B1 (ko) | BiVO₄가 담지된 산화티탄, 그 제조 방법 및 항바이러스성 조성물 | |
TWI581713B (zh) | Antiviral compositions, antiviral agents, photocatalysts and virus inactivation methods | |
JP2016113331A (ja) | BiVO4が担持された酸化チタンの製造方法および抗ウイルス性組成物 | |
JP2015205254A (ja) | 光触媒組成物、抗ウイルス剤及び抗菌剤 | |
JP2015150476A (ja) | 酸化チタンとCuOとを含有する光触媒組成物 | |
JP2015134726A (ja) | 抗ウイルス性組成物、その製造方法及びウイルス不活化方法 | |
JP2018111063A (ja) | 光触媒材料、光触媒材料の製造方法、抗ウイルス剤、抗菌剤、光触媒コーティング組成物、及び光触媒塗装体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14883138 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2016503943 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20167015783 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 14883138 Country of ref document: EP Kind code of ref document: A1 |